Certara (CERT) vs Red Violet (RDVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Red Violet (RDVT) has outperformed Certara (CERT) over the past year, gaining 53.2% versus a loss of 30.7%. Over five years, RDVT leads with a +145.2% price change compared with -76.3% for CERT. Certara is the larger company by market cap ($1.37 billion vs $1.25 billion), about 1.1 times the size.
On valuation, Certara trades at a lower forward P/E (23.0x vs 44.2x for Red Violet).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERT | RDVT |
|---|---|---|
| Share price | $8.96 | $77.85 |
| Market cap | $1.37B | $1.25B |
| 1-day change | -3.34% | -0.22% |
| YTD return | +1.70% | +36.70% |
| 1-year return | -30.70% | +53.19% |
| 5-year return | -76.32% | +145.20% |
| P/E ratio (TTM) | — | 68.29 |
| Forward P/E | 23.04 | 44.23 |
| EPS (TTM) | $-0.14 | $1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.30 | $81.80 |
| 52-week low | $4.45 | $33.40 |
| Distance from 52-week high | -32.63% | -4.82% |
| Analyst consensus | buy | none |
| Avg. price target upside | -3.79% | +8.54% |
| Average volume | 3.09M | 228.69K |
| Shares outstanding | 152.54M | 16.05M |
| Employees | 1,515 | 250 |
| Sector | Healthcare | Technology |
| Industry | Health Information Services | Software - Application |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RDVT has outperformed CERT by 83.9 percentage points over the past year.
- The two companies sit in different sectors: Certara in Healthcare and Red Violet in Technology.
About Certara
CERT stock →Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Healthcare · Health Information Services · 1,515 employees
About Red Violet
RDVT stock →Red Violet, Inc., an analytics and information solutions company, specializes in proprietary technologies and applying analytical capabilities to deliver identity intelligence in the United States. It offers idiCORE, an investigative solution used to address various organizational challenges, which include due diligence, risk mitigation, identity authentication, fraud detection and prevention, customer acquisition, and regulatory compliance; and FOREWARN, an app-based solution that provides instant knowledge before face-to-face engagement with a consumer, as well as helps professionals to identify and mitigate risk.
Technology · Software - Application · 250 employees
CERT vs RDVT FAQ
Which is bigger, Certara or Red Violet?
Certara (CERT) is larger, with a market capitalization of $1.37B compared with $1.25B for Red Violet (RDVT).
Which stock has performed better over the past year, CERT or RDVT?
RDVT returned +53.19% over the past 12 months, compared with -30.70% for CERT (price return, excluding dividends). Past performance does not predict future results.
Are Certara and Red Violet in the same industry?
No. Certara is in the Healthcare sector, while Red Violet is in Technology.